Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

214
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
214
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

414
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
414
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

586
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
586
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

554
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
554
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

430
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
430
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Tradipitant: First Approval.

Drugs·2026
Same author

Depemokimab: First Approval.

Drugs·2026
Same author

Sibeprenlimab: First Approval.

Drugs·2026
Same author

Zongertinib: First Approval.

Drugs·2026
Same author

Rilzabrutinib: First Approval.

Drugs·2025
Same author

Dorocubicel: First Approval.

Molecular diagnosis & therapy·2025

相关实验视频

Updated: Jan 6, 2026

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.5K

埃林扎内坦:第一次批准

Arnold Lee1

  • 1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.

Drugs
|November 12, 2025
PubMed
概括
此摘要是机器生成的。

埃林扎内坦是经批准用于与更年期相关的血管运动症状 (VMS) 的新型非激素治疗. 这种针对神经素的治疗有效地减少了VMS的频率和严重程度,标志着女性健康的显著进步.

更多相关视频

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles
09:57

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

2.3K
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

54.0K

相关实验视频

Last Updated: Jan 6, 2026

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.5K
Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles
09:57

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

2.3K
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

54.0K

科学领域:

  • 药理学 药理学 是一个学科.
  • 神经科学是一个神经科学.
  • 妇女健康 妇女健康

背景情况:

  • 血管运动症状 (VMS),如热和夜间出汗,在绝经期间显著影响女性的生活质量.
  • 目前对VMS的治疗方法通常涉及激素替代疗法,这可能会带来潜在的风险,不适合所有人.
  • 需要安全有效的非激素疗法来管理中度至重度的VMS.

研究的目的:

  • 总结一下elinzanetant的发展里程碑,这是一种用于VMS的新型非激素疗法.
  • 要突出作为神经素-1 (NK1) 和神经素-3 (NK3) 抗剂的elinzanetant的作用机制.
  • 提出临床证据,支持elinzanetant在减少VMS频率和严重性的有效性.

主要方法:

  • 作为一个小分子,非激素抗剂,以NK1和NK3受体为目标的elinzanetant的开发.
  • 进行了包括OASIS研究在内的临床试验,以评估elinzanetant对VMS的安全性和有效性.
  • 对临床试验数据的分析,以证明VMS频率和严重程度的减少.

主要成果:

  • 埃林扎涅坦 (Elinzanetant) 显著减少了与更年期相关的中度至重度VMS的频率和严重程度.
  • 针对神经素的治疗调节了过活的kisspeptin/neurokinin B/dynorphin神经元的活性.
  • 在OASIS的临床试验提供了强有力的证据,以elinzanetant的有效性.

结论:

  • 埃林扎内坦在治疗静脉样综合征方面取得了重大进展,提供了一个非激素治疗选择.
  • 该药物的批准标志着解决中度至重度VMS的妇女未满足需求的里程碑.
  • 埃林扎涅坦特的作用机制为管理更年期症状提供了一种新的方法.